Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
CE Teunissen, IMW Verberk, EH Thijssen… - The Lancet …, 2022 - thelancet.com
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …
recent results have shown that they could become a reality. Convincing data generated with …
[HTML][HTML] Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies
Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
Abstract Introduction Blood‐based Alzheimer's disease (AD) biomarkers provide
opportunities for community studies and across ethnic groups. We investigated blood …
opportunities for community studies and across ethnic groups. We investigated blood …
[HTML][HTML] Current and future biomarkers in multiple sclerosis
J Yang, M Hamade, Q Wu, Q Wang, R Axtell… - International journal of …, 2022 - mdpi.com
Multiple sclerosis (MS) is a debilitating autoimmune disorder. Currently, there is a lack of
effective treatment for the progressive form of MS, partly due to insensitive readout for …
effective treatment for the progressive form of MS, partly due to insensitive readout for …
Blood neurofilament light: a critical review of its application to neurologic disease
Neuronal injury is a universal event that occurs in disease processes that affect both the
central and peripheral nervous systems. A blood biomarker linked to neuronal injury would …
central and peripheral nervous systems. A blood biomarker linked to neuronal injury would …
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities
JA Syrjanen, MR Campbell… - Alzheimer's & …, 2022 - Wiley Online Library
Introduction Blood‐based biomarkers of amyloid pathology and neurodegeneration are
entering clinical use. It is critical to understand what factors affect the levels of these markers …
entering clinical use. It is critical to understand what factors affect the levels of these markers …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
A Pichet Binette, S Janelidze, N Cullen… - Alzheimer's & …, 2023 - Wiley Online Library
Introduction Plasma biomarkers will likely revolutionize the diagnostic work‐up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
The multifaceted role of neurofilament light chain protein in non-primary neurological diseases
The advancing validation and exploitation of CSF and blood neurofilament light chain
protein as a biomarker of neuroaxonal damage has deeply changed the current diagnostic …
protein as a biomarker of neuroaxonal damage has deeply changed the current diagnostic …
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
P Benkert, S Meier, S Schaedelin… - The Lancet …, 2022 - thelancet.com
Background Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that
is used not only to monitor disease activity and response to drugs and to prognosticate …
is used not only to monitor disease activity and response to drugs and to prognosticate …
[HTML][HTML] Renal function is associated with blood neurofilament light chain level in older adults
S Akamine, N Marutani, D Kanayama, S Gotoh… - Scientific reports, 2020 - nature.com
Neurofilament light chain (NfL) is a novel biomarker of neurodegenerative diseases. It is
detectable in the peripheral blood, allowing low-invasive assessment of early signs of …
detectable in the peripheral blood, allowing low-invasive assessment of early signs of …